Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
This Tiny Neon Frog Dwells in the Clouds - 2Iran-backed militias reassert power in Iraq, proving the Islamic axis is still standing
- 3The most effective method to Pick The Right Speakers
- 4Let them eat (Taylor Swift) cake: The baker turning A-listers into life-size desserts
- 5Authentic Urban areas: Rich Legacy and Lively Societies
- Three killed as unfinished building collapses on church service in Ghana
- Explosions at Burundi ammunition depot kill civilians, witnesses say
- Israeli strikes on Beirut, as Hezbollah and Iran attack Israel
- Relive NASA's historic Artemis 2 launch to the moon in these stunning photos
- 'Heated Rivalry' is just the tip of the iceberg. How hockey became the sexiest sport
- The most effective method to Augment Benefits in Gold Speculation: Systems and Tips
- Help Your Business with Master Web based Promoting Arrangements
- Boeing's troubled capsule won't carry astronauts on next space station flight
- Former Peruvian President Pedro Castillo sentenced for conspiracy
